DSN
PCRX icon

D. Scott Neal’s Pacira BioSciences PCRX Stock Holding History

D. Scott Neal’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed -$9K – 175
2017
Q4 		$9K Hold
200
– – 0.01% 130
2017
Q3 		$8K Hold
200
– – ﹤0.01% 140
2017
Q2 		$10K Hold
200
– – 0.01% 142
2017
Q1 		$9K Hold
200
– – 0.01% 121
2016
Q4 		$6K Hold
200
– – ﹤0.01% 129
2016
Q3 		$7K Hold
200
– – 0.01% 121
2016
Q2 		$7K Hold
200
– – 0.01% 121
2016
Q1 		$11K Sell
200
-200
-50% -$11.7K 0.01% 99
2015
Q4 		$31K Buy
+400
New +$22.6K 0.02% 71

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return